

## THE MANAGEMENT OF PREMENSTRUAL SYNDROME: RESULTS OF A QUESTIONNAIRE SURVEY OF WOMEN IN LVIV PHARMACIES, UKRAINE

Khrystyna Makukh, Oksana Horodnycha, Oksana Nepyivoda

**The aim.** To establish the prevalence of PMS symptoms and evaluate the medication management of this disorder in Lviv.

**Materials and methods.** The objects of the study were: scientific publications related to the problem of PMS; the results ( $n=105$ ) of the survey. Methods applied: systematization, generalization, comparison, questionnaire. The statistical analyses (descriptive statistics, univariable analysis using simple logistic regression, multiple logistic regression) were performed with SPSS Trial.

**Results.** The prevalence of PMS among the surveyed was high (83.8 %). The most common complaints are abdominal and/or low back pain (46.6 %) and increased irritability/aggression (43.2 %). Almost half (46.6 %) of women who experienced PMS consult a pharmacist, and only 23.9 % seek medical advice. At the same time, 87.5 % ( $n=77$ ) of women (among those suffering from PMS) use medicines to alleviate/eliminate the symptoms of PMS. Nonsteroidal anti-inflammatory drugs (77.6 %), sedatives (36.8 %), and complex herbal remedies that affect the genital system (18.4 %) are the most common drugs for PMS.

Choosing the way of PMS management, 44.8 % of women would prefer herbal medicines to synthetic ones. Both previous using of synthetic drugs for PMS and adverse drug reactions to synthetic drugs have a statistically significant contribution to a positive attitude towards herbal remedies ( $p=0.004$  and  $p=0.026$ , respectively).

**Conclusion.** PMS is a common medical and social issue. Achieving effective and safe medication management of PMS requires the joint participation of a physician, pharmacist, and the patient in terms of compliance and lifestyle adjustments

**Keywords:** premenstrual syndrome, symptoms, management, questionnaire, pharmacotherapy, nonsteroidal anti-inflammatory drugs, herbal remedies, risk factors

### How to cite:

Makukh, K., Horodnycha, O., Nepyivoda, O (2022). The management of premenstrual syndrome: results of a questionnaire survey of women in Lviv pharmacies, Ukraine. ScienceRise: Pharmaceutical Science, 3 (37), 27–33. doi: <http://doi.org/10.15587/2519-4852.2022.260186>

© The Author(s) 2022

This is an open access article under the Creative Commons CC BY license hydrate

### 1. Introduction

Premenstrual syndrome (PMS) is a disorder that encompasses clinically significant somatic and psychological symptoms during the luteal phase of the menstrual cycle, leading to substantial distress and impairment in functional capacity disappearing within a few days of the onset of menstruation [1]. In different countries, the prevalence of PMS ranges 12 % [2] to 86 % [3] of the female population, with the pooled worldwide prevalence at 48 % [4].

The most common symptoms of PMS include mood swings, decreased concentration, aggression, irritability, depression, anxiety, tearfulness, breast tenderness, abdominal and/or low back pain, swelling, weakness, sweating, headache, vomiting, nausea, diarrhoea, and some else psychological and physical symptoms [5, 6]. Thus, PMS is both a medical problem and a social one due to the deterioration of women's quality of life, the development of family and intimate maladaptation, the worsening of relationships with others, and decreased efficiency of working or study activities [7]. Numerous factors, such as stress level, age, body mass index, and marital status, impact the severity of PMS [8].

Different approaches are used for the management of PMS [8]. Although recent studies [9, 10] ob-

served the effectiveness of drug-free treatment of PMS (for instance, exercises, swimming), women still widely use medications to alleviate symptoms of PMS [5, 8]. Nonsteroidal anti-inflammatory drugs [5, 6], antidepressants, oral contraceptives, vitamins, and herbal supplements are the most common drug classes used for this purpose [2].

In Ukraine, numerous studies have been conducted on the problem of PMS. However, they are mainly concerned with studying hormonal disorders and pathology of the reproductive system [11, 12], the effectiveness of some medications [13], the impact of PMS on quality of life [14], etc. There is limited data about both (1) the prevalence of PMS symptoms among women of reproductive age and (2) the evaluation of its drug management in Ukraine, which determined the relevance and purpose of this study.

**The aim of the study.** To establish the prevalence of PMS symptoms and evaluate the medication management of this disorder in Lviv.

### 2. Research planning (methodology)

To perform this study and achieve the objectives, the authors created a 4-step algorithm.

*Step 1.* Goal setting and design of the study (literature search and analysis of worldwide publications on PMS, defining the purpose of the study, definition of objects and methods of the research, development of a survey instrument, content validation, and adjustment of the first version of questionnaire, approval the final version of survey instrument).

*Step 2.* Data collection and preliminary processing (survey of study participants, analysis of fulfilment of questionnaires, exclusion of the questionnaires from the final analysis due to missing information, entering the data into a customized database in SPSS).

*Step 3.* Statistical analysis and interpretation (analysis of the survey results with appropriate statistical and mathematical methods: descriptive statistics, univariable analysis, multiple logistic regression; presenting the results).

*Step 4.* Drafting the manuscript and critical revision (systematization and analysis of the results, comparing these findings with other studies, making conclusions, and defining recommendations to improve the PMS medication management).

### 3. Materials and methods

The questionnaire-based study was conducted in 3 pharmacy networks in Lviv, Ukraine, from June to December 2020. Totally 116 women of different ages, places of residence, professions, and fields of activity agreed to be included in the study sample. However, data from 105 questionnaires were included in the final analysis (11 questionnaires were excluded because of missing responses).

The survey instrument was a questionnaire of 20 questions related to the problem of PMS. A panel of 10 experts (gynecologists and pharmacists) examined the survey instrument for content validity. After calculating the indexes of validity, two questions were eliminated from the questionnaire. Thus, the final version of the survey instrument included 18 questions.

The statistical analyses were performed with SPSS Trial. Descriptive statistics described the qualitative (presented as frequencies and percentages) and quantitative (presented as mean±standard deviation (*SD*)) variables. To figure out the factors that contribute to women's adherence to herbal remedies, a univariable analysis was conducted using simple logistic regression on each independent variable (age, employment, number of symptoms of PMS, using synthetic medications for alleviation/elimination the symptoms of PMS in the past, adverse drug reaction occurrence after using synthetic medications for alleviation/elimination the symptoms of PMS in the past). Variables with a  $P \leq 0.25$  was considered statistically significant and were included in the multiple logistic regression. Multiple logistic regression was performed with forward and backward Wald tests. Results were presented as adjusted odds ratio (OR), 95 % confidence interval (CI) for OR, and P-value for the variables included in the final model. A value of  $P < 0.05$  was statistically significant.

#### *Ethics approval.*

The study received ethical approval from the Human Research Ethics Committee of Danylo Halytsky Lviv National Medical University No. 10 in December 2019.

### 4. Results

The average age of respondents was 26.4±8.6 years (range 19–48), with the prevalence of women under 25 years. Among the 105 females involved into the final analysis, 83.8 % experienced PMS. Out of them, 48.9 % of participants had at least one symptom of PMS regularly (monthly), 33.0 % – irregularly, and 18.1 % – rarely (Table 1). Women complained mainly of 1–3 symptoms of PMS, which occurred 2–14 days before menstruation (Table 1).

Table 1

Main characteristics of participants ( $n=105$ )

Main characteristics	$n$ (%)
Age, years	
min-max	19–48
average±SD*	26.4±8.6
Age (range), years	
18–25	75 (71.4)
26–40	19 (18.1)
>40	11 (10.5)
Employment:	
study and/or work	75 (71.4)
unemployed	30 (28.6)
PMS symptoms:	
yes	88 (83.8)
monthly	43 (48.9)**
irregularly	29 (33.0)**
rarely	16 (18.1)**
no	17 (16.2)
Number of symptoms of PMS	
1–3	46 (52.3)**
4–6	22 (25.0)**
7–9	9 (10.2)**
>10	7 (8.0)**

Note: \* – *SD* standard deviation; \*\* – women ( $n=88$ ) who had PMS were considered as 100 %

The most common symptoms of PMS were: (1) abdominal and/or low back pain and (2) increased irritability/aggression, observed in 46.6 % and 43.2 % of study participants, respectively. Increased appetite and changes in taste (36.4 %), apathy, tearfulness (33.0 %), loss of emotional self-control (33.0 %), breast tenderness (31.8 %), and depressed mood (30.7 %) were also common (Fig. 1).

Much fewer women complained of (1) decreased attention, (2) isolation, (3) nightmares (11.5 % among those suffering from PMS each), (4) high blood pressure, (5) headache, (6) pain radiating to the eyeballs (10.2 % each), (7) bone pain (9.0 %), (8) heart pain (8.0 %) (9) and nausea/vomiting (3.4 %).

According to the survey results, 68.6 % and 31.4 % of participants consider (1) chronic stress and (2) inflammatory diseases of the genital system to be the main factors contributing to the occurrence of PMS, respectively. At the same time, both frequent pregnancy (8.6 % of study participants) and late reproductive age (6.7 %) have the fewest influence on the development of PMS.

We found that almost half (46.6 %) of women who experience PMS symptoms consult a pharmacist,

and only 23.9 % seek medical advice. However, 87.5 % ( $n=77$ ) of respondents (among those suffering from PMS) use medications for the management of PMS. Most of them (67.6 %) take drugs periodically (for severe pain or other symptoms that are “annoying”), 27.3 % – monthly, and 5.2 % of respondents – use medicines for a long time (Fig. 2).

More than half of the respondents (54.5 %) take medicines from their own experience, 26.0 % of pa-

tients – according to the pharmacist’s recommendations, 11.7 % – to the doctor’s advice, and 7.8 % – to the Internet.

Nonsteroidal anti-inflammatory drugs (most often ibuprofen) are the most frequently used for the medication management of PMS (77.6 %), followed by sedatives (36.8 %), complex herbal remedies that affect the genital system (18.4 %), estrogens (15.8 %), hemostatic drugs (10.5 %), hormonal contraceptives (7.9 %), and folk remedies (5.3 %) (Fig. 3).




Fig. 1. The most common symptoms ( $n=13$ ) of PMS in the study participants: \* the total percentage does not equal 100 % because the responders could choose a few answers simultaneously




Fig. 2. The frequency distribution of using medications for the management of PMS




Fig. 3. The distribution of the medications used for the treatment of PMS: the total percentage does not equal 100 % because the responders could choose a few answers simultaneously

81.8 % ( $n=63$ ) of study participants observed the effectiveness of the medicines. At the same time, 18.2 % of women reported that their condition did not improve. Moreover, 28.6 % of study participants had different adverse drug reactions.

According to our findings, 52.4 % ( $n=55$ ) of respondents believe that herbal remedies are effective. In addition, 44.8 % ( $n=47$ ) of women would prefer herbal remedies to synthetic medications choosing the way of PMS management. It was determined that factors contributing to women’s adherence to herbal remedies include: (1) using synthetic medications for alleviation/elimination of the symptoms of PMS in the past (OR=0.234; 95 %CI 0.095–0.642,  $p=0.004$ ) and (2) adverse drug reaction occurrence after using synthetic medications for alleviation/elimination the symptoms of PMS in the past (OR=3.192; 95 %CI 1.152–8.848,  $p=0.026$ ) (Tables 2, 3).

Table 2

Univariable analysis of factors associated with the women’s adherence to herbal remedies for the management of PMS

Variables	Crude OR (95 % CI)	Wald Statistics (df)	<i>P</i> value <sup>a</sup>
Age	0.991 (0.950-1.034)	0.168 (1)	0.682
Number of symptoms of PMS	0.992 (0.871–1.128)	0.016 (1)	0.898
Employment:			
unemployed	1.000		
study and/or work	0.898 (0.384–2.101)	0.062 (1)	0.804
Using synthetic medications for alleviation/elimination the symptoms of PMS in the past			
yes	1.000		
no	0.336 (0.136–0.826)	5.652 (1)	0.017
Adverse drug reaction occurrence after using synthetic medications for alleviation/elimination the symptoms of PMS in the past			
no	1.000		
yes	2.082 (0.800–5.414)	2.260 (1)	0.133

Note: <sup>a</sup> – simple logistic regression (*P*-values by Wald test), significant at  $P \leq 0.25$

Table 3

Factors associated with the women’s adherence to herbal remedies for the management of PMS, final model

Variables	Adjusted OR <sup>a</sup> (95 % CI)	Wald Statistics (df)	<i>P</i> value <sup>b</sup>
Using synthetic medications for alleviation/elimination the symptoms of PMS in the past			
yes	1.000		
no	0.234 (0.095–0.642)	8.234 (1)	0.004
Adverse drug reaction occurrence after using synthetic medications for alleviation/elimination the symptoms of PMS in the past			
no	1.000		
yes	3.192 (1.152–8.848)	4.978 (1)	0.026

Note: Multicollinearity and interaction term were checked and were not found. Hosmer-Lemeshow test, classification table and the area under the ROC-curve were applied to check the model fitness and reported to be fit; <sup>a</sup> – adjusted to account for other predictors in the model; <sup>b</sup> – multiple logistic regression (*P*-values by forward and backward Wald tests), significant at  $P < 0.05$

The study found that 53.3 % of women need different information on PMS. Evidence-based data about the effectiveness of medications and the principles of rational pharmacotherapy of PMS were the most frequently required, which reported 35.7 % and 32.1 % of women, respectively (Fig. 4).




Fig. 4. Women’s answers to questions “What type of PMS-related information do you need the most?”

### 5. Discussion

The prevalence of PMS in Ukrainian women is high and in this study was about 84 %. The rates of PMS vary significantly across different countries and study populations [2, 3, 5]. For instance, the prevalence of PMS in France is 12 % [15], in Poland – 42 % [16], Brazil – 47 % [17], Ethiopia – 53 % [18], Nigeria – 69 % [19], Nepal – 72 % [20], Spain – 73 % [21], Iran – 74 % [5], Thailand – 86 % [3]. A wide range of prevalence rates in different studies might be due to using various tools of measurement and data collection methods [3, 4, 6]. Moreover, attitude and perception of PMS by women can lead to overestimating the symptoms [2, 3, 22].

More than half (52.3 %) of participants complained of 1 to 3 symptoms of PMS, 25 % – from 4 to 6 simultaneously. At the same time, about 18 % of the female population experienced seven or more symptoms. The most common manifestations of PMS were both physical and psychological disorders, including abdominal and/or low back pain (46.6 %) and increased irritability and aggression (43.2 %), followed by tearfulness, apathy (33.0 %) and loss of emotional self-control (33.0 %). This distribution confirms the results of the previous study in Iran, where low back pain and mood swings were the main complaints of PMS (59.1 % and 64.9 %, respectively) [5]. However, other studies established a considerably high proportion of other disorders. For instance, in Pakistan the most common symptoms were irritability, anger, depression, breast tenderness and gastrointestinal disorders [6], in Thailand – breast tenderness and angry outbursts [3].

According to our findings, 68.6 % and 31.4 % of respondents consider constant stress and inflammatory diseases of the genital system as the main risk factors of PMS, respectively. A lot of studies have investigated the risk factors of PMS so far [18]. As described in scientific literature, the presence of PMS is associated with age [16, 17, 23], lower education and unemployment [17], early menarche (<12 years) [23], sedentary life-style [17, 24, 25], stress and depression [17, 24, 26]. Also, there is a statistically significant association between the

occurrence of PMS and smoking [17, 25], taking alcohol [26], eating habits, such as regular coffee, and fast-food consumption [25].

PMS is a common cause of taking medications [5, 8]. We found that more than 87 % of women who experienced PMS, cope with PMS using at least one drug. In other countries, this rate is significantly lower and ranges from 51 % [6] to 77 % [5]. Almost 82 % of our participants taking medicines observe the effectiveness. However, 18 % of women do not feel alleviation. A possible explanation of this could be the fact that the sustained therapeutic effect of some medications (complex homeopathic remedies, herbal remedies that affect the genital system) for the management of PMS can be achieved only with prolonged use (at least two to three months) [27].

In this study, almost 88 % of women took medicines for self-medication. About 12 % of participants used medications according to a prescription. This result is like findings observed in other studies, where 70.2 % of women take drugs without a doctor's advice [5], and only 18.7 % consult the doctor on PMS [21]. *Mohib et al.* [6] explained it by the embarrassment associated with PMS in society and underestimating the importance of this problem among women.

According to our results, nonsteroidal anti-inflammatory drugs are the most frequently used for the medication management of PMS. This is consistent with the findings of some foreign studies [5, 6]. However, in Italy hormone contraceptives are most used for this purpose [21], in Jordan – herbal remedies [28]. In present study, we found positive women's attitudes towards herbal remedies. It was established that women's adherence to herbal medicines for the management of PMS is associated with (1) using synthetic medications for alleviation/elimination of the symptoms of PMS in the past (OR=0,234; 95 % CI 0.095–0.642,  $p=0.004$ ), and (2) adverse drug reaction after using synthetic medicines for alleviation/elimination the symptoms of PMS in the past (OR=3.192; 95 % CI 1.152–8.848,  $p=0.026$ ).

More than half of the respondents (53.3 %) involved in this study would like to receive additional information on PMS, particularly evidence-based medication management of this disorder. Hence, we analyzed, summarized, and systematized the evidence on the effectiveness of the most used medicines (nonsteroidal anti-inflammatory drugs) and drugs to which women are most prone (plant origin drugs) (Table 4).

Table 4

Clinical efficacy of medicines for PMS

Medications/plants	Strength of recommendation
Nonsteroidal anti-inflammatory drugs [29]	A
Chasteberry ( <i>Vitex Agnus-castus</i> ) [30, 31]	B
St. John's wort ( <i>Hypericum perforatum</i> ) [32–34]	C
Black cohosh ( <i>Cimicifuga racemosa</i> ) [35, 36]	C

According to the evidence-based search, nonsteroidal anti-inflammatory drugs are effective against pain in women with PMS (level of evidence A) [29]. However, this group of drugs has a pronounced ulcerogenic effect on the mucous membrane of the gastrointestinal tract [27]. Therefore, the duration of nonsteroidal anti-inflammatory drugs usage (particularly in self-medication) should not exceed three days [29]. Herbal remedies with chasteberry (*Vitex Agnus-castus*) inhibit the secretion of dopamine and follicle-stimulating hormone, normalize the hormonal imbalance of the estrogen-progesterone system, and reduce prolactin secretion [30, 31]. Medications containing St. John's wort (*Hypericum perforatum*) are effective in eliminating behavioral disorders in PMS (level of evidence C) [32–34]. Medicines based on black cohosh (*Cimicifuga racemosa*) facilitate “hot flashes”, reduce sweating, normalize nervous stress, and eliminate headaches, depression, anxiety, and insomnia (level of evidence C) [35, 36].

**Study limitations.** All data were obtained from retrospective self-reporting survey. Thus, original information was based on the participant's subjective assessment which could result in over- or underestimation of some findings.

**Further prospective studies** are needed to avoid bias.

Only 5 factors were included in the regression analysis to establish the women's adherence to herbal remedies for medication management of PMS. Hence, future studies are needed to explore the impact of other characteristics on adherence.

Other important limitations of this study were the sample size and carrying out the survey only in one city which limits the generalizability of our findings. However, this study provides valuable results for evaluating the prevalence of PMS and its management.

## 7. Conclusions

1. The prevalence of PMS was high (83.8 %). The most common symptoms of PMS were abdominal and/or low back pain (46.6 %), followed by increased irritability/aggression (43.2 %).

2. More than 87 % of women who experienced at least one symptom of PMS used medications for the management of PMS: nonsteroidal anti-inflammatory drugs (77.6 %), sedatives (36.8 %), complex herbal remedies that affect the genital system (18.4 %). This distribution indicates the multicomponent use of drugs and, hence, the need for clinical and pharmaceutical evaluation of drug management of PMS.

3. Self-medication of PMS is a common problem because 88 % of women take drugs without medical advice. At the same time, more than half of the respondents (53.3 %) would like to receive additional information on PMS. Thus, we believe that achieving effective and safe medication management of PMS requires the joint work of a physician, pharmacist, and the patient (in terms of compliance and lifestyle adjustments).

4. Women with PMS have a positive attitude towards herbal remedies. Both previous using of synthetic drugs for PMS and adverse drug reactions to synthetic drugs have a statistically significant contribution to a positive attitude towards herbal remedies ( $p=0.004$  and  $p=0.026$ , respectively).

5. The literature analysis showed that drugs commonly used for PMS (nonsteroidal anti-inflammatory drugs) have the level of evidence A. At the same time,

herbal remedies based on chasteberry have level B, black cohosh – level C, and St. John's wort – level C.

#### Conflict of interest

The authors declare that they have no conflicts of interest.

#### Financing

The study was performed without financial support.

#### References

1. Yesildere Saglam, H., Orsal, O. (2020). Effect of exercise on premenstrual symptoms: A systematic review. *Complementary Therapies in Medicine*, 48, 102272. doi: <http://doi.org/10.1016/j.ctim.2019.102272>
2. Hofmeister, S., Bodden, S. (2016). Premenstrual syndrome and premenstrual dysphoric disorder. *American family physician*, 94 (3), 236–240. Available at: <https://www.aafp.org/afp/2016/0801/p236.html>
3. Buddhahunyakan, N., Kaewrudee, S., Chongsomchai, C., Soontrapa, S., Somboonporn, W., Sothornwit, J. (2017). Premenstrual syndrome (PMS) among high school students. *International Journal of Women's Health*, 9, 501–505. doi: <http://doi.org/10.2147/ijwh.s140679>
4. Direkvand-Moghadam, A., Sayehmiri, K., Delpisheh, A., Sattar, K (2014). Epidemiology of premenstrual syndrome (pms) – a systematic review and meta-analysis study. *J Clin. Diagn Res*, 8 (2), 106–109. doi: <http://doi.org/10.7860/jcdr/2014/8024.4021>
5. Shahbazi, F., Eslampanah, Z., Niaparast, M. (2020). Prevalence of symptoms and medication use among female medical students and pharmacy clients with premenstrual syndrome: a cross-sectional study in Iran. *Journal of Pharmacy Practice and Research*, 50 (1), 55–60. doi: <http://doi.org/10.1002/jppr.1609>
6. Mohib, A., Zafar, A., Najam, A., Tanveer, H., Rehman, R. (2018). Premenstrual Syndrome: Existence, Knowledge, and Attitude Among Female University Students in Karachi. *Cureus*, 10 (3), e2290. doi: <http://doi.org/10.7759/cureus.2290>
7. Dennerstein, L., Lehert, P., Keung, L. S., Pal, S. A., Choi, D. (2010). Asian study of effects of premenstrual symptoms on activities of daily life. *Menopause International*, 16 (4), 146–151. doi: <http://doi.org/10.1258/mi.2010.010035>
8. Hamaideh, S. H., Al-Ashram, S. A., Al-Modallal, H. (2013). Premenstrual syndrome and premenstrual dysphoric disorder among Jordanian women. *Journal of Psychiatric and Mental Health Nursing*, 21 (1), 60–68. doi: <http://doi.org/10.1111/jpm.12047>
9. Maged, A. M., Abbassy, A. H., Sakr, H. R. S., Elsawah, H., Wagih, H., Ogila, A. I., Kotb, A. (2018). Effect of swimming exercise on premenstrual syndrome. *Archives of Gynecology and Obstetrics*, 297 (4), 951–959. doi: <http://doi.org/10.1007/s00404-018-4664-1>
10. Mohebbi Dehnavi, Z., Jafarnejad, F., Sadeghi Goghary, S. (2018). The effect of 8 weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome: a clinical trial study. *BMC Women's Health*, 18 (1). doi: <http://doi.org/10.1186/s12905-018-0565-5>
11. Pakharenko, L. V. (2014). Hormonal aspects of premenstrual syndrome. *Women's health*, 10 (96), 144–146.
12. Tatarchuk, T. F., Zakharenko, N. F., Manoliak, I. P. (2018). Premenstrual syndrome. Pathogenetic aspects of treatment. *Reproductive Endocrinology*, 5 (43), 50–54. doi: <http://doi.org/10.18370/2309-4117.2018.43.50-54>
13. Franchuk, O. S., Franchuk, M. O. (2019). Treatment of premenstrual syndrome with the use of adaptol and sedative preparations of plant origin. *Actual Problems of Pediatrics, Obstetrics and Gynecology*, 1, 136–139. doi: <http://doi.org/10.11603/24116-4944.2019.1.10202>
14. Bulavenko, O. V., Palapa, V. V., Dzis, N. P. (2014). Investigation of life quality in women of early reproductive age with edematous form of premenstrual syndrome. *Reports of Vinnytsia National Medical University*, 18 (2), 508–512. Available at: <https://dspace.vnmdu.edu.ua/handle/123456789/5133>
15. Potter, J., Bouyer, J., Trussell, J., Moreau, C. (2009). Premenstrual Syndrome Prevalence and Fluctuation over Time: Results from a French Population-Based Survey. *Journal of Women's Health*, 18 (1), 31–39. doi: <http://doi.org/10.1089/jwh.2008.0932>
16. Czajkowska, M., Drosdzol-Cop, A., Gałazka, I., Naworska, B., Skrzypulec-Plinta, V. (2015). Menstrual Cycle and the Prevalence of Premenstrual Syndrome/Premenstrual Dysphoric Disorder in Adolescent Athletes. *Journal of Pediatric and Adolescent Gynecology*, 28 (6), 492–498. doi: <http://doi.org/10.1016/j.jpag.2015.02.113>
17. Bianco, V., Cestari, A. M., Casati, D., Cipriani, S., Radici, G., Valente, I. (2014). Premenstrual syndrome and beyond: life-style, nutrition, and personal facts. *Minerva ginecologica*, 66 (4), 365–375. Available at: <https://pubmed.ncbi.nlm.nih.gov/25020055/>
18. Geta, T. G., Woldeamanuel, G. G., Dassa, T. T. (2020). Prevalence and associated factors of premenstrual syndrome among women of the reproductive age group in Ethiopia: Systematic review and meta-analysis. *PLOS ONE*, 15 (11), e0241702. doi: <http://doi.org/10.1371/journal.pone.0241702>
19. Ezeh, O., Ezeh, C. (2016). Prevalence of premenstrual syndrome and coping strategies among school girls. *African Journal for The Psychological Studies of Social Issues*, 19 (2), 111–119. Available at: <https://www.ajol.info/index.php/ajpsii/article/view/176111>
20. Shrestha, D. B., Shrestha, S., Dangol, D., Aryal, B. B., Shrestha, S., Sapkota, B., Rai, S. (2019). Premenstrual Syndrome in Students of a Teaching Hospital. *Journal of Nepal Health Research Council*, 17 (2), 253–257. doi: <http://doi.org/10.33314/jnhrc.v0i0.1213>
21. Lete, I., Dueñas, J. L., Serrano, I., Doval, J. L., Martínez-Salmeán, J., Coll, C. et. al. (2011). Attitudes of Spanish women toward premenstrual symptoms, premenstrual syndrome and premenstrual dysphoric disorder: results of a nationwide survey. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 159 (1), 115–118. doi: <http://doi.org/10.1016/j.ejogrb.2011.06.041>
22. Śliwerski, A., Koszałkowska, K. (2021). The Influence of Depression on Biased Diagnosis of Premenstrual Syndrome and Premenstrual Dysphoric Disorder by the PSST Inventory. *Life*, 11 (11), 1278. doi: <http://doi.org/10.3390/life11111278>

23. Abeje, A., Berhanu, Z. (2019). Premenstrual syndrome and factors associated with it among secondary and preparatory school students in Debreworkos town, North-west Ethiopia, 2016. *BMC Research Notes*, 12 (1). doi: <http://doi.org/10.1186/s13104-019-4549-9>
24. Yoshimi, K., Shiina, M., Takeda, T. (2019). Lifestyle Factors Associated with Premenstrual Syndrome: A Cross-sectional Study of Japanese High School Students. *Journal of Pediatric and Adolescent Gynecology*, 32 (6), 590–595. doi: <http://doi.org/10.1016/j.jpag.2019.09.001>
25. Seedhom, A. E., Mohammed, E. S., Mahfouz, E. M. (2013). Life Style Factors Associated with Premenstrual Syndrome among El-Minia University Students, Egypt. *ISRN Public Health*, 2013, 1–6. doi: <http://doi.org/10.1155/2013/617123>
26. Rezende, A. P. R., Alvarenga, F. R., Ramos, M., Franken, D. L., Dias da Costa, J. S., Pattussi, M. P., Paniz, V. M. V. (2022). Prevalence of Premenstrual Syndrome and Associated Factors Among Academics of a University in Midwest Brazil. *Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics*, 44 (2), 133–141. doi: <http://doi.org/10.1055/s-0041-1741456>
27. The State Register of Drugs of Ukraine. Available at: <http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument>
28. Albsoul-Younes, A., Alefishat, E., Farha, R. A., Tashman, L., Hijjij, E., AlKhatib, R. (2017). Premenstrual syndrome and premenstrual dysphoric disorders among Jordanian women. *Perspectives in Psychiatric Care*, 54 (3), 348–353. doi: <http://doi.org/10.1111/ppc.12252>
29. Marjoribanks, J., Ayeleke, R. O., Farquhar, C., Proctor, M. (2015). Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. *Cochrane Database of Systematic Reviews*. doi: <http://doi.org/10.1002/14651858.cd001751.pub3>
30. Cerqueira, R. O., Frey, B. N., Leclerc, E., Brietzke, E. (2017). Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. *Archives of Women's Mental Health*, 20 (6), 713–719. doi: <http://doi.org/10.1007/s00737-017-0791-0>
31. Ooi, S. L., Watts, S., McClean, R., Pak, S. C. (2020). Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis. *Journal of Women's Health*, 29 (2), 262–278. doi: <http://doi.org/10.1089/jwh.2019.7770>
32. Canning, S., Waterman, M., Orsi, N., Ayres, J., Simpson, N., Dye, L. (2010). The Efficacy of Hypericum perforatum (St John's Wort) for the Treatment of Premenstrual Syndrome: a randomized, double-blind, placebo-controlled trial. *CNS Drugs*, 24 (3), 207–225. doi: <http://doi.org/10.2165/11530120-000000000-00000>
33. Ghazanfarpour, M., Kaviani, M., Asadi, N., Ghaffarparand, F., Ziyadlou, S., Tabatabaee, H. R., Dehghankhalili, M. (2011). Hypericum perforatum for the treatment of premenstrual syndrome. *International Journal of Gynecology & Obstetrics*, 113 (1), 84–85. doi: <http://doi.org/10.1016/j.ijgo.2010.11.007>
34. Jang, S. H., Kim, D. I., Choi, M.-S. (2014). Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. *BMC Complementary and Alternative Medicine*, 14 (1). doi: <http://doi.org/10.1186/1472-6882-14-11>
35. Shahmohammadi, A., Ramezanpour, N., Mahdavi Siuki, M., Dizavandi, F., Ghazanfarpour, M., Rahmani, Y. et. al. (2019). The efficacy of herbal medicines on anxiety and depression in peri- and postmenopausal women: A systematic review and meta-analysis. *Post Reproductive Health*, 25 (3), 131–141. doi: <http://doi.org/10.1177/2053369119841166>
36. Leach, M. J., Moore, V. (2012). Black cohosh (*Cimicifuga* spp.) for menopausal symptoms. *The Cochrane database of systematic reviews*. doi: <http://doi.org/10.1002/14651858.cd007244.pub2>

*Received date 09.05.2022*

*Accepted date 23.06.2022*

*Published date 30.06.2022*

**Khrystyna Makukh\***, PhD, Associate Professor, Department of HealthCare Management, Pharmacotherapy and Clinical Pharmacy, Danylo Halytsky Lviv National Medical University, Pekarska str., 69, Lviv, Ukraine, 79010

**Oksana Horodnycha**, PhD, Assistant, Department of HealthCare Management, Pharmacotherapy and Clinical Pharmacy, Danylo Halytsky Lviv National Medical University, Pekarska str., 69, Lviv, Ukraine, 79010

**Oksana Nepyivoda**, Assistant, Department of HealthCare Management, Pharmacotherapy and Clinical Pharmacy, Danylo Halytsky Lviv National Medical University, Pekarska str., 69, Lviv, Ukraine, 79010

*\*Corresponding author: Khrystyna Makukh, e-mail: makuh.hrustyna@gmail.com*